Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

As Lars Fruergaard Jørgensen steps, Novo Nordisk seeks new leadership while production hurdles impact the competitive ...

Dow Jones Top Company Headlines at 11 AM ET: Ozempic Drugmaker’s CEO Pushed Out Amid Weight-Loss Market Challenges | Charter, ... Ozempic Drugmaker’s CEO Pushed Out Amid Weight-Loss Market ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Ireland has pivoted to oppose contentious European Union reforms aimed at broadening access to new drugs and medicines, ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

Novo Nordisk announces CEO transition as Lars Fruergaard Jørgensen departs amid Wegovy market share losses to Zepbound and ongoing supply chain disruptions ...